These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 10327061)

  • 1. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.
    Adachi M; Taki T; Ieki Y; Huang CL; Higashiyama M; Miyake M
    Cancer Res; 1996 Apr; 56(8):1751-5. PubMed ID: 8620488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer.
    Higashiyama M; Taki T; Ieki Y; Adachi M; Huang CL; Koh T; Kodama K; Doi O; Miyake M
    Cancer Res; 1995 Dec; 55(24):6040-4. PubMed ID: 8521390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of CD151 gene expression in non-small cell lung cancer.
    Tokuhara T; Hasegawa H; Hattori N; Ishida H; Taki T; Tachibana S; Sasaki S; Miyake M
    Clin Cancer Res; 2001 Dec; 7(12):4109-14. PubMed ID: 11751509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.
    Adachi M; Taki T; Konishi T; Huang CI; Higashiyama M; Miyake M
    J Clin Oncol; 1998 Apr; 16(4):1397-406. PubMed ID: 9552043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
    Miyake M; Nakano K; Itoi SI; Koh T; Taki T
    Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.
    Tomizawa Y; Adachi J; Kohno T; Hamada K; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Yokota J
    Clin Cancer Res; 1999 May; 5(5):1139-46. PubMed ID: 10353749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model.
    Takeda T; Hattori N; Tokuhara T; Nishimura Y; Yokoyama M; Miyake M
    Cancer Res; 2007 Feb; 67(4):1744-9. PubMed ID: 17308116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.
    Uchida S; Shimada Y; Watanabe G; Li ZG; Hong T; Miyake M; Imamura M
    Br J Cancer; 1999 Mar; 79(7-8):1168-73. PubMed ID: 10098753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection and prognostic significance of micrometastasis in peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation therapy].
    Chen TF; Jiang GL; Zhang YQ; Wang LJ; Fu XL; Qian H; Wu KL; Zhao S
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):365-8. PubMed ID: 17892133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma.
    Erovic BM; Pammer J; Hollemann D; Woegerbauer M; Geleff S; Fischer MB; Burian M; Frommlet F; Neuchrist C
    Head Neck; 2003 Oct; 25(10):848-57. PubMed ID: 12966509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.